Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Proof-of-Concept Study to Investigate the Safety and Efficacy of NLX-112 (Befiradol) in Parkinson's Disease Patients with Troublesome L-DOPA-Induced Dyskinesia

Trial Profile

A Phase 2, Proof-of-Concept Study to Investigate the Safety and Efficacy of NLX-112 (Befiradol) in Parkinson's Disease Patients with Troublesome L-DOPA-Induced Dyskinesia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Befiradol (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Neurolixis
  • Most Recent Events

    • 12 Mar 2019 According to a Neurolixis media release, the company look forward to initiating this clinical study with NLX-112 later this year.
    • 12 Mar 2019 According to a Neurolixis media release, the US Food and Drug Administration (FDA) has approved Neurolixis Investigational New Drug (IND) application for NLX-112 and also authorized this phase 2 study in Parkinson's disease patients with troublesome L-DOPA-induced dyskinesia.Preparation and submission of the IND application was supported by funding from Parkinsons UK.
    • 08 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top